← Latest news 
Emcure ramps up R and D and bets on global acquisitions for next wave of growth
Business
Published on 6 May 2026
The GLP 1 partnership could reshape its pipeline
Emcure Pharmaceuticals is accelerating domestic expansion while scaling R&D and manufacturing capacity. The company is also scouting acquisition opportunities both in India and abroad, aiming to add new products to fuel growth. A key driver is its partnership with Novo Nordisk for GLP-1 therapies, alongside a pipeline of complex injectables poised to support momentum ahead.
- Emcure is expanding in India with more R&D and manufacturing
- It is evaluating acquisitions domestically and internationally
- New products are expected to drive the next growth phase
- Novo Nordisk GLP-1 partnership plus complex injectables power the outlook
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times